Current Report Filing (8-k)
May 18 2016 - 10:56AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
May 18, 2016
ORAMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
DELAWARE
|
|
001-35813
|
|
98-0376008
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
Hi-Tech Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel
|
|
91390
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
+972-2-566-0001
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01. Other Events.
On
May 18, 2016, Oramed Pharmaceuticals Inc. announced positive top-line results from its Phase 2b clinical trial, designed to evaluate
the safety and efficacy of its oral insulin capsule ORMD-0801 in patients with type 2 diabetes. The double blind, 28 day, randomized
trial of 180 patients was conducted at 33 clinical sites in the United States under a Food and Drug Administration (FDA) Investigational
New Drug (IND) protocol. The trial’s primary objective, a significant reduction of weighted mean night-time glucose, was
successfully achieved.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
May
18, 2016
|
ORAMED PHARMACEUTICALS INC.
|
|
|
|
|
By:
|
/s/ Nadav Kidron
|
|
Name:
|
Nadav Kidron
|
|
Title:
|
President and CEO
|
3
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Apr 2023 to Apr 2024